| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12692652 | IVR | 60 mg/kg | 60 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Necrosis of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | - | No significant effects observed | - | |
| IVR | 16 mg/kg | - | No significant effects observed | - | |
| IVR | 32 mg/kg | - | No significant effects observed | - | |
| IVR | 20 mg/kg | - | No significant effects observed | - | |
| IVR | 3 mg/kg | - | No significant effects observed | - | |
| IVR | 63 mg/kg | - | No significant effects observed | - | |
| IVR | 8 mg/kg | - | No significant effects observed | - | |
| IVR | 30 mg/kg | 30 mg/kg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Necrosis of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Increased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| PMID:3184199 | IVR | 50 mg/L | 50 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/L | 50 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 15 mg/L | 15 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 15 mg/L | 15 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 1.5 mg/L | - | No significant effects observed | - | |
| IVR | 0.5 mg/L | - | No significant effects observed | - | |
| IVR | 5 mg/L | 5 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.